Most Read This Week
- Treatment Selection for mRCC Based on Gene Expression
- Dr. Farzanna Haffizulla: Making Time and Making That Time Count
- Dr. Farzanna Haffizulla: Work, Life, and Everything in Between
- A Pan-Cancer Analysis of PBAF Complex Mutations and Their Association With Immunotherapy Response
- Novel Therapies for mRCC
Recently Updated
- Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant RCC Setting
- Quality-Adjusted Survival With First-Line Cabozantinib or Sunitinib for Advanced RCC in the CABOSUN Randomized Clinical Trial (Alliance)
- Real-World Safety and Efficacy of Nivolumab for Second- and Later-Line Treatment of Metastatic RCC
- Cabozantinib Plus Atezolizumab for Non-Clear Cell Renal Cell Carcinoma
- Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell Carcinoma